|
Adenoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This unique disturbance of the cAMP-PDE pathway observed in the majority of <i>AIP</i>-mutation positive adenomas could contribute to their well-described poor response to somatostatin analogs and may support a role in tumorigenesis.
|
30941100 |
2019 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To correlate responses with the adenoma somatostatin receptor (SSTR) profile.
|
28323931 |
2017 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of somatostatin receptor subtypes (SSTRs) in pituitary growth hormone- (GH-) secreting adenomas may predict the response to somatostatin analogues (SSA).
|
28396686 |
2017 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
When presurgical somatostatin receptor ligand (SRL) therapy is administered, T2-hypointense adenomas have better hormonal responses and have greater tumor shrinkage.
|
28197813 |
2017 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RESULTS IHC of SSTR subtypes in the different cohorts showed SSTR2 staining intensity scores higher than SSTR5 in TSHoma, acromegaly and prolactinoma, whereas the expression of SSTR5 was stronger than SSTR2 in corticotropinoma and NFPA.
|
28434012 |
2017 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In sporadic acromegaly, downregulation of AIP protein of the adenomas associates with invasive tumor features and reduced responsiveness to somatostatin analogues.
|
27998919 |
2017 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To explore granulation pattern and presence of gsp oncogene in acromegaly with correlations to clinical and biochemical variables and to the effect of treatment with somatostatin analogues (SA), as well as to describe granulation pattern in adenomas with and without SA pretreatment.
|
21722151 |
2012 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Decreased protein content in somatotroph adenomas has been associated with increased tumor size, invasion, and poor response to somatostatin analog (SA) treatment, but the potential mechanisms of EMT progression in these adenomas are lacking.
|
22585092 |
2012 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Differential expression of somatostatin receptor subtype-related genes and proteins in non-functioning and functioning adrenal cortex adenomas.
|
21720716 |
2011 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the 663T allele was significantly associated with a younger age of acromegaly diagnosis (unstandardized regression coefficient β=-10.4; P=0.002), increased body mass index (β=4.1; P=0.004), higher number of adenoma resection (P<0.001) and lack of observable tumor shrinkage after somatostatin analog treatment (P=0.014).
|
21810856 |
2011 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective was to examine the protein expression of E-cadherin in somatotroph pituitary adenomas in relation to adenoma size, invasiveness, and somatostatin analog (SMS) efficacy.
|
20335450 |
2010 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased endogenous somatostatin (SST) tone may also slow the conversion from hyperplastic to adenomatous state because mRNA levels for SST receptors, sst2 and sst5, were elevated in hyperplastic pituitaries, whereas adenomas were associated with a decline in sst1 and sst5 mRNA.
|
19342460 |
2009 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.
|
17941904 |
2008 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrated that TSH-secreting adenomas express sstr1, 2A, 3 and 5 mRNAs, predominantly sstr2A, and in addition to the expression of sstr2 mRNA, the expression level of sstr5 mRNA may be a factor affecting the tumor shrinkage by somatostatin analogues against TSH-secreting adenomas.
|
17420609 |
2007 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No correlation between SSTR2 and SSTR5 genotypes, responsiveness to somatostatin therapy, and mRNA expression in the removed adenomas (n = 10) was found.
|
15914528 |
2005 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.
|
15994755 |
2005 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, GHRH or forskolin treatments did not significantly affect DNA synthesis in adenoma cells in the presence or absence of somatostatin (2/2 and 4/4 adenomas, respectively).
|
12807513 |
2003 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the effects of SRIF and a SSTR1 selective agonist, BIM-23926, on GH and prolactin (PRL) secretion and cell viability in primary cultures deriving from 15 GH- and PRL-secreting adenomas expressing SSTR1.
|
12788890 |
2003 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
1) the distribution of SSTR is not significantly different between NFPA and GH-producing adenomas; and 2) somatostatin receptor scintigraphy reveals a higher uptake in GH-producing adenomas which is not significantly related to either SSTR distribution or tumor volume.
|
11434667 |
2001 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
|
11231991 |
2001 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, studies using somatostatin (SRIF) analogs preferential for either the SRIF receptor 2 (SSTR2) or the SSTR5 subtype demonstrated a variable suppression of GH and PRL release from GH-secreting human adenomas.
|
10690891 |
2000 |
|
Adenoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As the gsp oncogene is associated with an increased octreotide (somatostatin agonist) sensitivity, a group of 8 somatotroph adenomas bearing the gsp mutation (gsp+) and another group of 16 adenomas without the mutation (gsp-) were analyzed, all of them presenting variable octreotide sensitivities.
|
10443675 |
1999 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Genomic DNA coding for somatostatin receptor (SSTR2) from each adenoma was PCR amplified and sequenced.
|
9059557 |
1997 |
|
Adenoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using reverse transcription-PCR, we investigated gene expression of the five receptors in 47 human normal and cancerous tissues or cell lines from pancreatic and colorectal origin. mRNAs of somatostatin receptor subtypes were detected in 98% of samples, with more than two mRNA subtypes being expressed in 55% of cases. sst1, sst4, and sst5 were heterogeneously expressed in both normal and cancerous tissues; sst3 was rarely or not expressed. sst2 was present in normal pancreatic tissues but was absent in exocrine pancreatic carcinomas and their metastases. sst2 mRNAs were detected in normal colon, sporadic polyadenomas, and 50% of Dukes' stage B and 20% of Dukes' stage C carcinomas but were undetectable in Dukes' stage D carcinomas, hepatic metastases, and adenomas from familial adenomatous polyposis.
|
8620499 |
1996 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine whether specific SSTR subtype mRNA expression is required for SRIF inhibition of GH secretion, five somatotroph adenomas were treated with 10(-7) mol/L SRIF in vitro, and significant inhibition of GH release occurred in all adenomas.
|
7714115 |
1995 |